EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

Impact of comorbidities on prostate cancer‐specific mortality: A population‐based cohort study

Tenaw Tiruye iD, David Roder, Liesel M FitzGerald iD, Michael O'Callaghan, Kim Moretti, Gillian E Caughey, Kerri Beckmann iD

The Prostate · 2024-09 · 84 (12) · 1138-1145

DOI: 10.1002/pros.24750 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift The Prostate, online erschienen am 26.05.2024. Verfasst von Tenaw Tiruye und 6 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Epidemiology and Population Health Research Group, Allied Health and Human Performance, University of South Australia, Adelaide, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Comorbidity. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Movember Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To assess the impact of comorbidities on prostate cancer mortality.

Methods

We studied 15,695 South Australian men diagnosed with prostate cancer between 2003 and 2019 from state‐wide administrative linked data sets. Comorbidity was measured 1‐year before prostate cancer diagnosis using Rx‐Risk, a medication‐based comorbidity index. Flexible parametric competing risk regression was used to estimate the independent association between comorbidities and prostate cancer‐specific mortality. Specific common comorbidities within Rx‐Risk (cardiac disorders, diabetes, chronic airway diseases, depression and anxiety, thrombosis, and pain) were also assessed to determine their association with mortality. All models were adjusted for sociodemographic variables, tumor characteristics, and treatment type.

Results

Prostate cancer‐specific mortality was higher for patients with a Rx‐Risk score ≥3 versus 0 (adjusted sub‐hazard ratio (sHR) 1.34, 95% CI: 1.15–1.56). Lower comorbidity scores (Rx‐Risk score 2 vs. 0 and Rx‐Risk score 1 vs. 0) were not significantly associated with prostate cancer‐specific mortality. Men who were using medications for cardiac disorders (sHR 1.31, 95% CI: 1.13–1.52), chronic airway disease (sHR 1.20, 95% CI: 1.01–1.44), depression and anxiety (sHR 1.17, 95% CI: 1.02–1.35), and thrombosis (sHR 1.21, 95% CI: 1.04–1.42) were at increased risk of dying from prostate cancer compared with men not on those medications. Use of medications for diabetes and chronic pain were not associated with prostate cancer‐specific mortality. All Rx‐Risk score categories and the specific comorbidities were also associated with increased risk of all‐cause mortality.

Conclusion

The findings showed that ≥3 comorbid conditions and specific comorbidities including cardiac disease, chronic airway disease, depression and anxiety, and thrombosis were associated with poor prostate cancer‐specific survival. Appropriate management of these comorbidities may help to improve survival in prostate cancer patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsComorbidityHumansMaleAgedMiddle AgedCohort StudiesAged, 80 and overSouth AustraliaDepressionHeart DiseasesDiabetes MellitusAnxiety

Stichwörter der Autor:innen

comorbiditymortalityprostate cancer

Autor:innen und Institutionen

  • Cancer Epidemiology and Population Health Research Group, Allied Health and Human Performance, University of South Australia, Adelaide, Australia.
  • School of Public Health, Debre Markos University, Debre Markos, Ethiopia.
  • Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia.
  • South Australian Prostate Cancer Clinical Outcomes Collaborative, Adelaide, Australia.
  • Flinders Health and Medical Research Institute, Flinders University, Adelaide, Australia.
  • Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.

ORCID-Profile: Tenaw Tiruye, Liesel M FitzGerald, Kerri Beckmann

Förderung

  • Movember Foundation

Zitieren

APA

Tiruye, T., Roder, D., FitzGerald, L. M., O'Callaghan, M., Moretti, K., Caughey, G. E., & Beckmann, K. (2024). Impact of comorbidities on prostate cancer‐specific mortality: A population‐based cohort study. The Prostate, 84(12), 1138-1145. https://doi.org/10.1002/pros.24750

Vancouver

Tiruye T, Roder D, FitzGerald LM, O'Callaghan M, Moretti K, Caughey GE, et al. Impact of comorbidities on prostate cancer‐specific mortality: A population‐based cohort study. The Prostate. 2024;84(12):1138-1145. doi:10.1002/pros.24750

BibTeX
@article{Tiruye2024,
  author = {Tiruye, Tenaw and Roder, David and FitzGerald, Liesel M and O'Callaghan, Michael and Moretti, Kim and Caughey, Gillian E and Beckmann, Kerri},
  title = {Impact of comorbidities on prostate cancer‐specific mortality: A population‐based cohort study},
  journal = {The Prostate},
  year = {2024},
  volume = {84},
  number = {12},
  pages = {1138--1145},
  doi = {10.1002/pros.24750}
}
Kostenlos starten →